Prevalence of antiretroviral drug resistance among naive Spanish patients infected with HIV;Prevalencia de resistencia a los fármacos antirretrovirales en pacientes Españoles infectados por el VIH y sin tratamiento previo

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 10, 2005, Pages 605-608

  Guerrero, Antonio ^a   Cañizares, Angelina ^b   Tomás, Sofía ^c   Velasco, David ^b   Cartelle, Mónica ^b  

^a HOSPITAL DE LA RIBERA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c Centro de Salud Nazaret   (Spain)

Author keywords

Antiretroviral; HIV; Primary resistance; Resistance; Sequencing

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; AZATHIOPRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE; RETROTRANSCRIPTASE; STAVUDINE; TENOFOVIR; TRANSCRIPTASE; UNCLASSIFIED DRUG; ZALCITABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; DISEASE DURATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SPAIN; STRUCTURAL GENE; VIRUS GENE;

EID: 29444447284     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(05)75040-0     Document Type: Article

References (25)

1. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
2. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Jonson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-26.
3. International AIDS Society-USA Panel. Update on Drug Resistance Mutations in HIV-1. Topics in HIV Medicine. 2001;9:31-3.
4. Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, et al. ERASE-3 Group. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS. 2001;15:1894-6.
5. Puig T, Pérez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS. 2000;14:727-32.
6. Pérez-Olmeda M, Del Romero J, Rubio A, Ruiz L, Rodríguez C, Leal M, et al. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. J Med Virol. 2001;63:85-7.
7. Gomez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998;12:1015-20.
8. Yerly S, Rakik A, Kinloch-de Loës S, Erb P, Vernazza P, Hirschel B, et al. Prevalence of transmission of zidovudine-resistant viruses in Switzerland. L'Etude suisse de cohorte VIH. Schweiz Med Wochenschr. 1996;126:1845-8.
9. Imrie A, Beveridge A, Geen W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175:1502-6.
10. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-11.
11. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-41.
12. Pillay D, Cane P, Shirley J, Porter K. Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS. 2000;14:906-8.
13. Dietrich U, Ruppach S, Gehring S, Knechten H, Knickmann M, Jager H, et al. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. AIDS. 1997;11:1532-3.
14. Plan Nacional del SIDA. Las Resistencias a los fármacos antirretrovirales: Utilización de los tests en la práctica asistencial. Madrid, 2000.
15. Kuritzkes D. Drug resistance testing: time to be used in clinical practice? AIDS Reviews. 1999;1:45-50.
16. Rodríguez-Rosado R, Briones C, Soriano V. Introduction of HIV drug resistance testing in clinical practice. AIDS. 1999;13:1007-14.
17. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-resistant HIV-1 variants. Lancet. 1999;354:729-33.
18. Little S, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-9.
19. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med. 1999;131:502-6.
20. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS. 2000;14:F17-23.
21. Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol. 1999;73:8448-56.
22. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-52.
23. Briones C, Mas A, Gómez-Mariano G, Altisent C, Menéndez-Árias L, Soriano V, et al. Dynamics of dominance of a dipeptide insertion in RT of HIV-1 from patients subjected to prolonged therapy. Virus Res. 2000;66:13-26.
24. Pérez-Olmeda M, Rubio A, Puig T, Gómez-Cano M, Ruiz L, Leal M, et al. Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens. Antiviral Ther. 1999;4:179-81.
25. Kaye S, Comber E, Tenant-Flowers M, Loveday C. The appearance of drug resistance associated point mutations in HIV-1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses. 1995;11:1221-5.